Semaglutide Trial Explores Easing Carb Counting for Type 1 Diabetics

For individuals with Type 1 Diabetes (T1D), managing blood glucose levels requires constant vigilance, including precise carbohydrate counting for every meal to dose insulin correctly. This meticulous calculation represents a significant daily burden, impacting quality of life and potentially leading to suboptimal glycemic control despite advancements like closed-loop insulin systems (artificial pancreases). This study addresses the critical need to reduce the cognitive load of carbohydrate counting in T1D patients by investigating if weekly Semaglutide can offer a solution.

As this is a recruiting trial, specific results are not yet available; however, the study aims to determine if weekly Semaglutide can significantly reduce the carbohydrate counting burden for individuals with Type 1 Diabetes who are utilizing closed-loop insulin therapy. Researchers hypothesize that Semaglutide, a GLP-1 receptor agonist, may improve glycemic stability and reduce post-meal glucose excursions, thereby allowing for more flexible carbohydrate intake without compromising overall glycemic control. The primary objective is to assess if Semaglutide can lead to a measurable reduction in the frequency or precision of carbohydrate counting required, while maintaining or improving key metrics of glycemic control such as time in range and HbA1c. Secondary endpoints are expected to include improvements in glycemic variability, a decrease in hypoglycemia rates, and an enhancement in patient-reported quality of life compared to the placebo group. The trial design anticipates that participants receiving Semaglutide will experience a significant decrease in the cognitive and emotional load associated with mealtime insulin adjustments.